$CRMD News

Needham Reiterates Buy on Cormedix, Maintains $15 Price Target

Cormedix Announces FDA Acceptance for Priority Review of Supplemental NDA for Rezzayo® (Rezafungin) for Prophylaxis of Invasive Fungal Diseases

CorMedix Therapeutics Says FDA Accepts sNDA Filing Seeking Approval Of REZZAYO For Prophylaxis Of Invasive Fungal Disease; PDUFA Target Action Date Set In Q1 2027

CRMD vs. PRTA: Which Stock Should Value Investors Buy Now?

Oppenheimer Initiates Coverage On Cormedix with Outperform Rating, Announces Price Target of $15

CorMedix (CRMD) Just Tripled Its Profits, But Guidance Barely Budged

Wall Street Analysts Think CorMedix (CRMD) Could Surge 67.73%: Read This Before Placing a Bet

CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference

CorMedix (CRMD) Upgraded to Buy: Here's Why

CorMedix (CRMD) Q2 2026 Earnings Call Transcript

Wall Street Analysts Believe CorMedix (CRMD) Could Rally 65.96%: Here's is How to Trade

CorMedix: Durable Commercial Base, But 2027 Is The Real Test

CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains

RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $14

CorMedix Inc. Q2 2026 Earnings Call Summary

Cormedix Inc (CRMD) (Q2 2026) Earnings Call Highlights: Record Revenue and Raised EBITDA ...

CorMedix Q2 Earnings Call Highlights

CorMedix CEO Expects Supplemental Filing For Fungal Disease Treatment By Q3 – CRMD Stock Sees Best Day In Nearly 10 Months After Earnings Beat

CorMedix Inc. (CRMD) Q2 2026 Earnings Call Transcript

CorMedix (CRMD) Q2 Earnings and Revenues Top Estimates